Stephen Hahn, FDA commissioner (AP Images)

Stephen Hahn: FDA will make some changes amid Covid-19 per­ma­nent

The FDA will look to per­ma­nent­ly im­ple­ment some of the process­es and poli­cies adopt­ed in its re­sponse to the Covid-19 pan­dem­ic, FDA com­mis­sion­er Stephen Hahn said dur­ing a vir­tu­al brief­ing host­ed by the Al­liance for a Stronger FDA on Mon­day.

Hahn’s state­ments dur­ing the brief­ing close­ly mir­rored state­ments he made in a pre-record­ed video FDA up­loaded to YouTube on Fri­day.

“As this pan­dem­ic has evolved, it was clear to all of us that some FDA process­es need­ed to be ad­just­ed to ac­com­mo­date the ur­gency of the pan­dem­ic and I think the en­tire FDA team has now seen first-hand that we need to take a crit­i­cal look at some of our process­es and poli­cies,” Hahn said.

Hahn added that many of the changes the agency will im­ple­ment “rep­re­sent an ac­cel­er­a­tion of where we were head­ed be­fore,” and in­clude sup­port for de­cen­tral­ized clin­i­cal tri­als, greater use of telemed­i­cine tech­nol­o­gy in clin­i­cal tri­als and work re­lat­ed to lab­o­ra­to­ry-de­vel­oped tests.

Hahn said he has in­struct­ed FDA staff “to iden­ti­fy the lessons learned from this pan­dem­ic and what ad­just­ments may be need­ed, not just to man­age this or fu­ture emer­gen­cies, but how to per­ma­nent­ly make FDA more ef­fi­cient in car­ry­ing out [its] reg­u­la­to­ry re­spon­si­bil­i­ties.”

Ad­di­tion­al­ly, Hahn said FDA is us­ing re­al-world ev­i­dence to mon­i­tor the use of med­ical prod­ucts dur­ing the pan­dem­ic. “We very much used re­al-world ev­i­dence and our Sen­tinel sys­tem and oth­er re­sources to look back at the re­al-world use of di­ag­nos­tic tests and med­ical prod­ucts and then ad­just our au­tho­riza­tions based on that,” he said, adding that re­al-world ev­i­dence can al­so help “to bet­ter un­der­stand dis­ease, de­scribe and mea­sure im­mu­ni­ty [and] un­der­stand the op­er­at­ing char­ac­ter­is­tics of tests.”

Hahn al­so ad­dressed con­flict of in­ter­est con­cerns stem­ming from the role of Cen­ter for Drug Eval­u­a­tion and Re­search (CDER) Di­rec­tor Janet Wood­cock and Cen­ter for Bi­o­log­ics Eval­u­a­tion and Re­search (CBER) Di­rec­tor Pe­ter Marks in over­see­ing the re­view of prod­ucts de­vel­oped to treat or pre­vent Covid-19.

Wood­cock and Marks were both ini­tial­ly slat­ed to take lead­er­ship roles on the Trump ad­min­is­tra­tion’s Op­er­a­tion Warp Speed. Short­ly af­ter the an­nounce­ment, Marks left his new role to fo­cus on head­ing CBER, while Wood­cock was tem­porar­i­ly re­as­signed to the Of­fice of the Com­mis­sion­er dur­ing her work on Op­er­a­tion Warp Speed.

“We have been very clear in writ­ing, but al­so ver­bal­ly, that we will main­tain our reg­u­la­to­ry in­de­pen­dence, so that Janet [Wood­cock] will not par­tic­i­pate in the reg­u­la­to­ry de­ci­sions around ther­a­peu­tics and Pe­ter and I will stay out­side of any de­ci­sion-mak­ing that Op­er­a­tion Warp Speed has to make with re­spect to med­ical prod­ucts so that we can main­tain our in­de­pen­dence,” Hahn said.

For a look at all End­points News coro­n­avirus sto­ries, check out our spe­cial news chan­nel.

RAPS: First pub­lished in Reg­u­la­to­ry Fo­cus™ by the Reg­u­la­to­ry Af­fairs Pro­fes­sion­als So­ci­ety, the largest glob­al or­ga­ni­za­tion of and for those in­volved with the reg­u­la­tion of health­care prod­ucts. Click here for more in­for­ma­tion.

How Pa­tients with Epilep­sy Ben­e­fit from Re­al-World Da­ta

Amanda Shields, Principal Data Scientist, Scientific Data Steward

Keith Wenzel, Senior Business Operations Director

Andy Wilson, Scientific Lead

Real-world data (RWD) has the potential to transform the drug development industry’s efforts to predict and treat seizures for patients with epilepsy. Anticipating or controlling an impending seizure can significantly increase quality of life for patients with epilepsy. However, because RWD is secondary data originally collected for other purposes, the challenge is selecting, harmonizing, and analyzing the data from multiple sources in a way that helps support patients.

$DNA is once again on NYSE; FDA clears Soliris chal­lenger for the mar­ket; Flag­ship’s think­ing big again with eR­NA; and more

Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add Endpoints Weekly. New to Endpoints? Sign up here.

I still remember the uncertainty in the air last year when nobody was sure whether ASCO would cancel their in-person meeting. But it’s now back again for the second virtual conference, and Endpoints News is here for it. Check out our 2-day event reviewing the landscape of cancer R&D and send news our way.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 105,400+ biopharma pros reading Endpoints daily — and it's free.

Re­gen­eron's Evkeeza shows promise in curb­ing high triglyc­erides, but will ge­net­ic dis­par­i­ties lim­it use?

When Regeneron scored an early approval for lipid lowering antibody Evkeeza back in February, the drugmaker cracked open a new pathway to lower abnormally high cholesterol levels. Now, Regeneron is chasing high triglycerides as well with some promising mid-stage data — but will genetic restrictions limit the drug’s use?

Regeneron’s Evkeeza (evinacumab) cut median triglyceride levels by more than 800 mg/dL (57%) in patients with a rare disorder causing abnormally high triglyceride levels compared with an overall increase of 50 mg/dL (1.8%) in participants on placebo, according to Phase II data presented Sunday at the virtual American College of Cardiology meeting.

Michael Dell (Richard Drew, AP Images)

'Dude, you're get­ting a Del­l' — as a new deep-pock­et biotech in­vestor

What happens when you marry longtime insiders in the global biotech VC game with the family fund of tech billionaire Michael Dell, a synthetic biology legend out of MIT and Harvard and the former director of the NCI?

Today, the answer is a newly financed, $200 million biotech SPAC now cruising the industry for a top player interested in finding a short cut to Nasdaq.

Orion Biotech Opportunities priced their blank check company today, raising $200 million with Dell’s multibillion-dollar MSD group’s commitment on investing another $20 million in a forward-purchase agreement.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

As­traZeneca's Farx­i­ga missed big on Covid-19 study, but it's tak­ing SGLT2 safe­ty da­ta as a sil­ver lin­ing

AstraZeneca hasn’t seen many setbacks in recent months for SGLT2 inhibitor Farxiga, which broke ground in heart failure and kidney disease regardless of diabetes diagnosis. But the British drugmaker had to admit defeat in taking Farxiga into Covid-19, but follow-up results add a bit of a silver lining to that trial’s safety data.

Of hospitalized Covid-19 patients dosed with AstraZeneca’s Farxiga, 11.2% experienced an organ failure or died after 30 days of therapy compared with 13.8% of those given placebo, according to follow-up data from the DARE-19 study revealed Sunday at the virtual American College of Cardiology meeting.

Pfiz­er, Bris­tol My­er­s' Eliquis flops in post-heart surgery pa­tients, spurring an 'un­ex­plained sig­nal' in cer­tain deaths

Pfizer and Bristol Myers Squibb’s non-warfarin blood thinner Eliquis has raced out to become the most prescribed drug of its class on the market — even overtaking warfarin’s long-time lead. But in tricky-to-treat patients after a valve replacement, an investigator-sponsored study couldn’t turn up benefit and raised a troubling safety signal.

Eliquis failed to show benefit over standard of care in preventing serious clinical outcomes after a transaortic valve replacement (TAVR) and was linked to an “unexplained signal” in a subset of populations with a higher rate of non-CV deaths who did not need blood thinners apart from the surgery, according to data presented Saturday at the virtual American College of Cardiology meeting.

Vas Narasimhan (Photographer: Simon Dawson/Bloomberg via Getty Images)

No­var­tis whiffs on En­tresto study af­ter heart at­tacks — but that does­n't mean it's go­ing down qui­et­ly

If Novartis learned one thing from its interaction with the FDA over its latest heart failure approval for Entresto, it was that missing a primary endpoint may not be the nail in the coffin. Now, Entresto has missed again on a late-stage study in high-risk heart patients, and it’s already sowing the seeds for a path forward regardless.

Novartis’ Entresto couldn’t best standard-of-care ramipril in staving off a composite of deaths and heart failure events in patients with left ventricular systolic dysfunction and/or pulmonary congestion who have had a prior heart attack, according to topline data from the Phase III PARADISE-MI study revealed Saturday at the virtual American College of Cardiology meeting.

Brazil­ian Covid vari­ant in Illi­nois leads to a pause in ship­ments of Lil­ly’s mAb com­bo

The US is pausing shipments of Eli Lilly’s Covid-19 treatment combo (bamlanivimab and etesevimab) to Illinois because of the increased frequency of the coronavirus variant that originated in Brazil, known also as the P.1 variant.

The FDA is now recommending that health care providers in Illinois instead use Regeneron’s monoclonal antibody combo therapy of casirivimab with imdevimab, which it said is likely to retain activity against the P.1 variant, until further notice.

BAR­DA slows its $9B en­gine for new Covid-19 ther­a­peu­tics

The Biomedical Advanced Research and Development Authority is cooling its jets in looking for new, potential Covid-19 treatments, at least in the near term.

An HHS spokesperson told Endpoints News via email, “to date, BARDA has obligated more than $9 billion for the development and/or purchase of 13 therapeutics, beginning in February 2020 with support to develop Regeneron’s monoclonal antibody therapeutic. Therapeutics are an important element of the COVID-19 response, and we are focused on the programs currently underway and/or in negotiation using the funds available to us.”